• AFP-Jiji


Already facing a daunting COVID-19 vaccination challenge, French and German authorities are fighting to convince more people that a jab from the pharma giant AstraZeneca is just as effective as others.

Stocks of the vaccines from the British-Swedish firm are going unused in both countries despite the desire to end a pandemic that has sparked a social and economic calamity on a scale not seen since World War II.

Only 273,000 doses of the jab developed by AstraZeneca and Oxford University have been administered in France out of 1.7 million received as of end-February, according to health ministry figures.

The poor take-up comes even as the target group for the jabs, health workers over 50 and people with other serious health risks, can get the vaccine directly from their doctor instead of waiting for appointments at vaccination centers.

Experts say it is also cheaper to produce than the two other vaccines approved for Europe, from Pfizer-BioNTech and Moderna, and does not require ultracold storage, making it easier to deploy.

But both France and Germany had refused to authorize AstraZeneca’s vaccine for people over 65, fanning fears over its effectiveness.

However, French Health Minister Olivier Veron said Monday that the country would now be made available to those between 65 and 75 with serious health risks.

Those over 75 will continue to receive the Moderna vaccine, he added.

AstraZeneca’s fumbled release of testing data last November, coupled with questions over its ability to halt new COVID-19 variants, added to the skepticism. Critics also note that U.S. regulators have yet to approve AstraZeneca’s jab.

But Jacques Battistoni, head of the MG France doctors’ union, last week denounced the widespread “AstraZeneca bashing” that was causing many vials to go unused.

And the country’s vaccination coordinator, Alain Fischer, complained last week that the “bad press” surrounding the shot was “deeply unfair.”

President Emmanuel Macron, who initially said the AstraZeneca jab was “quasi-ineffective” for people over 65, is now urging people to take it.

“If this is the vaccine I’m offered, obviously I would take it,” he said after a European Council meeting on Friday.

Study data released on Monday by English health authorities showed that the jab was “highly effective” in preventing serious illness in older people, with a more than 80% reduction in hospitalization.

Britain’s Health Secretary Matt Hancock, keen to talk up a British success story, claimed that the data was “slightly better for the Oxford jab than for Pfizer.”

The results and Veran’s announcement could now increase pressure on Germany to authorize the jab for the over-65s.

“I think in time the data emerging from the program will speak for itself and other countries will doubtless be very interested in it,” said Jonathan Van-Tam, deputy chief medical officer for England.

In Germany, calls are growing to widen the vaccine priority list to make sure no AstraZeneca shots go to waste.

By Feb. 23, 1.45 million doses had been delivered to Germany, but only 240,000 had been used.

The controversy has contributed to the government’s decision to move teachers and childcare workers from priority group three to group two.

But some regional leaders are urging Germany to go further still.

“Not a single AstraZeneca dose should be left over or thrown out,” said Bavarian leader Markus Soeder in comments published Sunday.

“Before that happens: vaccinate anyone who wants it,” he told the Bild am Sonntag newspaper. “Every day counts.”

Chancellor Angela Merkel and Germany’s 16 regional leaders meet on Wednesday to discuss the next steps in the fight against the pandemic.

Merkel herself praised the AstraZeneca shot as “a vaccine that can be trusted” in an interview last week. She pleaded with Germans not to pick and choose their vaccines.

Asked if she would lead by example and take the AstraZeneca vaccine herself, Merkel replied that she was not eligible for this particular jab given that she was 66 years old.

The STIKO commission “will very soon publish a new updated recommendation” after a study showed it to be effective for the elderly, its head Thomas Mertens said on Friday.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.